Increased thrombin generation among postmenopausal women using hormone therapy: Importance of the route of estrogen administration and progestogens

Menopause

Volumn 18, Issue 8, 2011, Pages 873-879

  Scarabin, Pierre Yves ^a,b   Hemker, H Coen ^c   Clément, Céline ^a,b   Soisson, Véronique ^a,b   Alhenc Gelas, Martine ^d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Hemostatic variables; Hormone therapy; Menopause; Thrombin generation

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; ESTROGEN; FIBRINOGEN; GESTAGEN; PROGESTERONE; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN;

ADULT; AGED; ARTICLE; AUTOMATION; CALIBRATION; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; HYPERCOAGULABILITY; NORMAL HUMAN; PHENOTYPE; POSTMENOPAUSE; SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; RISK FACTORS; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 80051551065     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31820eee88     Document Type: Article

References (33)

1. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580. (Pubitemid 39314963)
2. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166: 772-780.
3. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336: 1227-1231. (Pubitemid 351809317)
4. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432. (Pubitemid 36999704)
5. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-3500. (Pubitemid 43739566)
6. Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. J Thromb Haemost 2006;4:1259-1265.
7. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30: 340-345.
8. Renoux C, Dell'aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J Thromb Haemost 2010;8:979-986.
9. Olie V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among menopausal women. Curr Opin Hematol 2010;17:457-463.
10. Olié V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:488-493.
11. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845. (Pubitemid 46294724)
12. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335:239.
13. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17: 3071-3078. (Pubitemid 28016061)
14. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625. (Pubitemid 32293696)
15. Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008;90:642-672.
16. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-1676. (Pubitemid 37108215)
17. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23: 1116-1121. (Pubitemid 36713570)
18. Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DDM, van der Mooren M. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2006;26: 1660-1666. (Pubitemid 44288998)
19. Tans G, van HylckamaVlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003;122:465-470. (Pubitemid 36951632)
20. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006;296:397-402. (Pubitemid 44127523)
21. Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 2009;29:332-336.
22. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, et al. Impact of progestogens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004;2:1594-1600. (Pubitemid 40186176)
23. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 2001;86:1495-1500. (Pubitemid 34007524)
24. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Throm 2003;33:4-15. (Pubitemid 37449290)
25. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to protein C: a randomized cross-over study. Lancet 1999;354:2036-2040.
26. Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost 2010;8:1736-1744.
27. Eilertsen AL, LiestLl S, Mowinckel MC, Hemker HC, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost 2007;97:938-943. (Pubitemid 46939206)
28. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
29. Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olié V, Scarabin PY. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of the progestogen. Menopause 2010;17;1122Y1127.
30. Tchaikovski SN, van Vliet HA, Thomassen MC, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007;98:1350-1356. (Pubitemid 350239109)
31. Dielis AW, Castoldi E, Spronk HM, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008;6:125-131.
32. Thaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Throm Res 2010;126:5-11.
33. Hemker H, Béguin S. Phenotyping the clotting system. Thromb Haemost 2000;84:747-751.